References
- Brunning R D, Matutes E, Harris N L, Flandrin G, Vardiman J W, Bennett J, . Acute myeloid leukemia and myelodysplastic syndrome, therapy related. Pathology and Genetics: Tumours of Hematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H M Stein, J W Vardiman, et al. IARC, Lyon 2001; 89–91
- Vogler W R, Velez-Garcia E, Weiner R S, Flaum M A, Bartolucci A A, Omura G A, et al. A Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol 1992; 10: 1103–1111
- Nguyen T T, Schwartz E J, West R B, Warnke R A, Arber D A, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphoma, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005; 29: 617–624
- Bissery M-C, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 1995; 22: 3–16
- Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology 1995; 9: 1191–1199
- Consolini R, Pui C-H, Behm F G, Raimondi S C, Campana D. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998; 16: 907–913
- Avramis I A, Kwock R, Avramis V I. Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 2001; 21: 2281–2286
- Majlessipour F, Avramis I A, Kwock R, Weinberg K I, Avramis V I. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines. Anticancer Res 2002; 22: 1361–1368